Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06708299 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Study acronym: MAVERIC
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 10, 2026 (before its estimated September 21, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Cardiol Therapeutics Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Secondary endpoints: 1 to 2
    v19
  2. Site details revised at 1 of 27 sitesv18
  3. Site details revised at 1 of 27 sitesv17
  4. Study sites: 26 to 27v16
  5. Study description shortened, about 10 words
    • Study title shortened, about 2 words
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 23 to 26v14
  2. Study sites: 22 to 23
    • Eligibility criteria expanded, about 220 words
    • Secondary endpoint revised
    • Study description expanded, about 77 words
    v13
  3. Study sites revised (22)v12
  4. Study sites: 16 to 22v11
  5. Study sites: 7 to 16v10
  6. Eligibility criteria shortened, about 2 wordsv9
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 5 to 7
    • Start date changed from estimate of Mar 21, 2025 to Apr 7, 2025
    v8
  8. Primary completion date: Aug 28, 2026 to Sep 21, 2026
    • Study completion date: Sep 28, 2026 to Oct 21, 2026
    • Start date: Feb 28, 2025 to Mar 21, 2025
    v7
  9. Start date: Dec 15, 2024 to Feb 28, 2025
    • Primary completion date: Jun 15, 2026 to Aug 28, 2026
    • Study completion date: Jul 15, 2026 to Sep 28, 2026
    v6
  10. Phase: Phase 2/3 to Phase 3
    • Study description shortened, about 1 word
    v5
  11. 3 versions Re-verified since Nov 26, 2024, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.
Trial Details
NCT Number NCT06708299
Lead Sponsor Cardiol Therapeutics Inc.
Conditions
(from sponsor)		 Recurrent Pericarditis
Related terms Pericarditis
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov